NEW YORK (GenomeWeb) – Cambridge, UK-based Congenica today announced it has raised £2.2 million ($3.3 million) in Series A financing from Amadeus Capital Partners and Cambridge Innovation Capital.
The firm has developed Sapientia, a platform to screen whole-genome sequencing data to identify novel genetic mutations and highlight those associated with genetic disorders.
Congenica, a spinout of The Wellcome Trust Sanger Institute, will use the funds to further develop its technology, the firm said in a statement.
"We have an excellent investor base and have now achieved £5 million in funding and grants and which will help us take the technology into the clinic and accelerate our growth," Congenica CEO Tom Weaver said in a statement.
In March, Congenica received a share of £8 million in research grants awarded by Genomics England to improve genomic data analysis.